|
|
Post by phdedieu12 on Jan 27, 2023 9:16:08 GMT -5
Looks like 2 shares were traded, that could be your answer LOL
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2023 9:27:45 GMT -5
Off topic. Sports, what's going on with UTHR this morning? Up 13.5 % 2 shares traded...Never mind... |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2023 9:28:44 GMT -5
Looks like 2 shares were traded, that could be your answer LOL Ha, made ya look! |
|
|
|
Post by phdedieu12 on Jan 27, 2023 9:31:04 GMT -5
Looks like 2 shares were traded, that could be your answer LOL Ha, made ya look! Sure did!  |
|
|
|
Post by Thundersnow on Jan 31, 2023 15:51:41 GMT -5
Do you think UTHR has a problem with MNKD competing against them in the IPF space?? Mike highlighted the BI DRUG (Ninatnimb (sp?)) and kinda sounded excited about the progress.
|
|
|
|
Post by sr71 on Jan 31, 2023 16:01:52 GMT -5
Do you think UTHR has a problem with MNKD competing against them in the IPF space?? Mike highlighted the BI DRUG (Ninatnimb (sp?)) and kinda sounded excited about the progress. What if they're not? ...wink, wink  |
|
|
|
Post by phdedieu12 on Jan 31, 2023 16:03:09 GMT -5
Making a couple assumptions: MNKD-201 (nintedanib) indeed is in direct competition, and we're defining "has a problem" in terms of not being happy with MNKD. I can't imagine that any company is ever happy to have competition, look at how happy they are with LQDA as an example. But like we've done with Tyvaso, maybe this is just another molecule we need a partner for, a great partner like UTHR, and in this case maybe UTHR is thrilled that Mannkind is developing a new drug they can sell. Are you half empty or half full?
|
|
|
|
Post by hopingandwilling on Jan 31, 2023 16:27:59 GMT -5
If he was talking about nintedanib, why would he be excited about it? Nintedanib is sold under the name—Ofev, as a branded drug. It therefore should be protected from any competition until 2029? Just wondering!
|
|
|
|
Post by boca1girl on Jan 31, 2023 16:29:03 GMT -5
I thought (Ninatnimb (sp?)) would be product #2 with UTHR.
|
|
|
|
Post by akemp3000 on Jan 31, 2023 16:37:04 GMT -5
Or maybe UTHR has bigger plans that would eliminate this being a problem  |
|
|
|
Post by anderson on Jan 31, 2023 16:41:25 GMT -5
If he was talking about nintedanib, why would he be excited about it? Nintedanib is sold under the name—Ofev, as a branded drug. It therefore should be protected from any competition until 2029? Just wondering! Think it depends on formulation, notice the capsule dosage form is protected till 2029 but one of the formulations is only till 2024
3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Patent 7,119,093
Issued: October 10, 2006
Inventor(s): Roth; Gerald J. & Linz; Guenter & Sieger; Peter & Rall; Werner & Hilberg; Frank & Bock; Thomas
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulphonate of formula I and the use thereof as a pharmaceutical composition
Patent expiration dates:
February 21, 2024
✓
Drug substance
✓
Drug product
|
|
|
|
Post by mango on Jan 31, 2023 16:51:47 GMT -5
If he was talking about nintedanib, why would he be excited about it? Nintedanib is sold under the name—Ofev, as a branded drug. It therefore should be protected from any competition until 2029? Just wondering! It was approved in 2014 for IPF. No exclusivity. |
|
|
|
Post by hopingandwilling on Jan 31, 2023 16:54:59 GMT -5
You have confirmed my suggestion--you must read again what you posted---note the following --"pharmaceutical composition"---meaning that MNKD can't use their pharmaceutical composition which is the drug we are posting about.
|
|
|
|
Post by Clement on Jan 31, 2023 17:00:44 GMT -5
I thought (Ninatnimb (sp?)) would be product #2 with UTHR. Interesting ... I wondered about that too. Nintedanib is for NTM lung infection. But the press release concerning the original agreement with UTHR said that additional molecules would be for pulmonary hypertension. Of course, agreements can be modified or new agreements can be made. " In addition, MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the treatment of pulmonary hypertension. Each optioned product would be subject to the payment to MannKind of up to $40 million in additional option exercise and development milestone payments as well as a low double-digit royalty on net sales of any such product." investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-and-mannkind-announce-collaboration |
|
|
|
Post by mango on Jan 31, 2023 17:03:53 GMT -5
You have confirmed my suggestion--you must read again what you posted---note the following --"pharmaceutical composition"---meaning that MNKD can't use their pharmaceutical composition which is the drug we are posting about. You’re getting pharmaceutical composition and active pharmaceutical ingredient confused. MannKind is not violating the patent because they have their own unique pharmaceutical composition. MannKind uses their own patented carrier, which is FDKP aka Technosphere. |
|
